Dr. Gagandeep Brar, MD

Dr. Brar practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Brar's NPI, 1528323177, was assigned on July 10, 2012. Dr. Brar graduated from Ross University School of Medicine in 2012. Dr. Brar holds California license A132193.

Dr. Brar's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Brar's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Brar is also affiliated with Providence Holy Cross Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Brar to 2 more home health agencies and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brar practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Brar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Brar is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Brar's licenses on file in 2 states: California and New York.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, lung cancer, lymphoma and neutropenia among the conditions Dr. Brar treats.

CMS data shows 757 Medicare services from Dr. Brar across 5 procedure codes in 2024, for 214 Medicare patients. Medicare paid $79,400 for them.

CMS counts 214 Medicare patients who saw Dr. Brar in 2024. The largest group is 65 to 74, with 136 patients. 75% of them have high blood pressure, and 63% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brar's median patient age at 66, with 46% women.

In 2024, Dr. Brar wrote 488 Medicare Part D claims for 101 patients. 83% of them were for generic drugs. CMS names the drug for 332 of them, across 13 drugs with 11 or more claims each, at $173,438 in total drug cost. In 2023, CMS named 258 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Brar for performance year 2024, reported as part of a group. Dr. Brar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brar as offering telehealth.

Dmand AI links 22 papers to Dr. Brar, published from 2018 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular and Liver Neoplasms. Dr. Brar has published most often in J Clin Oncol. Dr. Brar's most frequent co-authors are Tim F. Greten, MD, David Erwin Kleiner, MD, PhD and Manish A. Shah, MD.

CMS Open Payments shows 27 general payments to Dr. Brar from 15 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Jazz Pharmaceuticals Inc. paid the most, $2,776.

Dr. Brar graduated from Ross University School of Medicine in 2012.

Dr. Brar is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.